Permissive Hypernatremia in Intracerebral Hemorrhage
For patients with large ICH (>30 mL) or symptomatic perihematomal edema, maintaining serum sodium at 140-150 mEq/L for 7-10 days is reasonable to minimize edema expansion and mass effect, but hypernatremia at hospital discharge (>145 mEq/L) is associated with increased post-discharge mortality and should be avoided. 1, 2
When to Consider Permissive Hypernatremia
The strategy of maintaining mild hypernatremia is not indicated for routine use in all ICH patients. Specifically:
Small hematomas without significant mass effect: No indication for routine mannitol or hypertonic saline (HTS), and therefore no need for permissive hypernatremia 1
Large ICH (volume >30 mL) or symptomatic perihematomal edema: Target serum sodium of 140-150 mEq/L for 7-10 days may be beneficial 1
Hyperosmolar Therapy Framework
The 2022 AHA/ASA guidelines establish that hyperosmolar therapy is the principal medical strategy for cerebral edema in ICH 3. However, the guidelines focus on acute management rather than sustained permissive hypernatremia protocols:
- Hypertonic saline is more effective than mannitol in equiosmolar doses for treating acutely elevated ICP 3
- Hyperosmolar therapy is typically administered in 4-6 hour intervals 3
- The duration of transient effects and whether these agents prevent poor outcomes remains unclear 3
Critical Safety Concern: Discharge Hypernatremia
A major pitfall is allowing hypernatremia to persist at hospital discharge. A large two-center study of 5,100 critically ill ICH patients found that discharge sodium >145 mEq/L was associated with:
- Adjusted odds ratio of 1.87 (95% CI 1.40-2.48) for 30-day post-discharge mortality 2
- This remained significant even after adjusting for age, race, gender, comorbidities, and sepsis 2
This suggests that while mild hypernatremia may be therapeutic during the acute phase for select patients with large hemorrhages, it must be normalized before discharge.
Practical Protocol for Permissive Hypernatremia
When indicated (large ICH >30 mL or symptomatic edema):
- Target range: 140-150 mEq/L 1
- Duration: 7-10 days 1
- Administration: HTS via continuous infusion (3%) or bolus (23.4%) through central line 1, 4
- Monitoring: Frequent serum sodium and chloride measurements 4
- Taper plan: Begin normalizing sodium levels well before anticipated discharge to ensure discharge sodium ≤145 mEq/L 2
Indications for Emergent Hyperosmolar Therapy
Separate from permissive hypernatremia, mannitol and HTS should be used emergently for 1:
- Worsening cerebral edema
- Elevated ICP
- Pending herniation
Key Caveats
- Avoid in small hemorrhages: No benefit and potential harm from unnecessary hypernatremia 1
- Monitor for complications: Mild adverse events are common but manageable with appropriate sodium/chloride monitoring 4
- Discharge planning is critical: The association between discharge hypernatremia and mortality suggests that normalization before discharge is essential 2
- Limited high-quality evidence: Most data on sustained hypernatremia protocols are retrospective or observational 4
The evidence does not support routine permissive hypernatremia for all ICH patients, but rather a selective approach for those with large hemorrhages or significant mass effect, with careful attention to normalizing sodium before hospital discharge.